FINWIRES · TerminalLIVE
FINWIRES

Applied Materials Poised for Multiyear Growth, Margin Expansion, BofA Securities Says

By

Applied Materials (AMAT) has "unprecedented" visibility into 2027 and 2028 as customers provide rolling eight-quarter forecasts and margins show structural improvement, BofA Securities said in a note Thursday.

Full-year 2026 systems sales are now expected to grow 30% year over year, up from a prior forecast of 20%, driven by advanced logic chips, DRAM memory and advanced packaging demand, the brokerage said.

The company's margin/free cash flow profile is improving, with semiconductor systems gross margins approaching 55% and operating margins trending toward levels seen at peers, according to the note.

The brokerage also highlighted strong growth prospects for advanced packaging and services businesses, while warning that mature-node exposure and higher operating expense intensity could weigh on growth.

The brokerage raised its 2026 and 2027 earnings per share estimates by 14% and 18%, respectively, and increased its price target to $540 from $465, while reiterating a buy rating.

Price: $436.59, Change: $-3.97, Percent Change: -0.90%

Related Articles

Australia

Ford Motor's Battery Storage Plan More Linked With AI Trade, RBC Capital Markets Says

Ford Motor (F) recently reiterating its battery energy storage business plans likely more linked with the AI trade rather than on business fundamentals, RBC Capital Markets said in a research report emailed Friday.The company will produce batteries domestically, making it eligible for regulatory benefits. The energy business value could range from $1 billion to $5 billion, assuming a 10% earnings before interest, taxes, depreciation, and amortization margin consistent with a systems integrator approach and 15% margins driven by a more insourced strategy at the high-end, analysts wrote.For the Ford Model E segment, the guided path to breakeven by 2029 is multi-pronged, given that the energy unit is expected to generate positive earnings before interest and taxes, legacy electric vehicle losses are likely to narrow, the universal EV platform launches in 2027, and European margins are likely to benefit from the Renault partnership, according to the note.The brokerage said it reiterated its sector perform rating on the stock and price target of $13 per share.Price: $13.37, Change: $-1.11, Percent Change: -7.67%

$F
Australia

Fiserv Sees Double-Digit EPS Growth Returning as It Expands Agentic AI Push, RBC Says

Fiserv (FISV) is positioning itself for a return to double-digit adjusted earnings growth while expanding its push into agentic AI and banking automation through its new AgentOS platform, RBC Capital Markets said.The investment firm said in a Thursday research note that AgentOS is designed to create AI agents that operate across banking workflows within regulated environments.Fiserv is collaborating with OpenAI and Amazon (AMZN) Bedrock AgentCore on the platform, with six financial institutions already participating in development efforts and two running agents in beta, RBC said.The firm also highlighted continued momentum in Merchant Solutions, where Clover represented about $3.3 billion in revenue in 2025.RBC said the company is focused on improving Core migration dynamics and reducing attrition through investments in service-level improvements and a more modular migration approach.RBC has an outperform rating with a $75 price target on Fiserv.Shares of the company were up 1.8% in Friday afternoon trading.Price: $54.44, Change: $+0.98, Percent Change: +1.83%

$FISV
Australia

Repligen Likely to Benefit From Diverse Growth Factors, RBC Says

Repligen (RGEN) is expected to benefit from diverse growth drivers in a strengthening bioprocessing market, RBC Capital Markets said in a Thursday note."Bioprocessing demand trends are the most robust in Tools, and Repligen is a pure play," the note said.The report also pointed to growth prospects at its commercial products, biosimilars, product replacement cycles, and a strategyreboot in China.The note said the growth drivers should enable the firm to return to mid-teens organic sales growth, as RBC resumes coverage of Repligen with an outperform rating and a $160 price target."The growth pressures associated with a specific gene therapy customer should lap next year, while several tailwinds...should ramp," the report said.Price: $105.97, Change: $+2.59, Percent Change: +2.50%

$RGEN